Neogen的股票大受打击,因为分析师降低价格目标,尽管内幕人士购买。 Neogen's stock takes a hit as analysts lower price targets, despite insider buying.

Neogen的股票面临降级, Guggenheim将价格目标降低至10.00美元, 但保持了“买买”评级, 而Piper Sandler则将目标降低至5.00美元, 并将其评为“中性”。 Neogen's stock has faced a downgrade with Guggenheim lowering its price target to $10.00 but maintaining a "buy" rating, while Piper Sandler dropped its target to $5.00 and rated it "neutral." 尽管最近一季度出现53.56%的负净差,但专门从事基因组诊断的Neogen公司最近购买了83 500股股票。 Despite a negative net margin of 53.56% in the latest quarter, Neogen, which specializes in genomics-based diagnostics, has seen insiders buy 83,500 shares recently. 12个月的平均价格目标现在为8.62美元,比11.85美元下降了27.26%,反映了市场和业绩的变化。 The average 12-month price target is now $8.62, down 27.26% from $11.85, reflecting market and performance shifts.